Monjuvi Patient Assistance Program

(tafasitamab-cxix)

Key Takeaways

  1. Monjuvi® (tafasitamab-cxix) is a CD19-directed monoclonal antibody approved, in combination with lenalidomide, for the treatment of certain adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).
  2. Following combination treatment with lenalidomide, eligible patients may continue Monjuvi as monotherapy until disease progression or unacceptable toxicity.
  3. Monjuvi does not carry an FDA Boxed Warning, but treatment requires monitoring for serious infections, myelosuppression, infusion-related reactions, and embryo-fetal toxicity associated with combination therapy with lenalidomide.
  4. Prescription Hope may help eligible individuals access manufacturer-sponsored patient assistance programs that can make Monjuvi more affordable.

 

Introduction

Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma that may return or stop responding after initial treatment. For adults who are not candidates for autologous stem cell transplant, additional treatment options may be needed to help control the disease.

Monjuvi is a targeted immunotherapy approved for use in combination with lenalidomide in certain adults with relapsed or refractory diffuse large B-cell lymphoma. After completing combination therapy, eligible patients may continue receiving Monjuvi alone until disease progression or unacceptable toxicity.

Because Monjuvi is a specialty biologic administered by intravenous infusion, treatment costs can vary based on insurance coverage, infusion services, and healthcare facility charges.

Prescription assistance programs may help eligible patients obtain Monjuvi at a more affordable cost.

What Is the Monjuvi Patient Assistance Program?

Understanding Monjuvi Prescription Assistance

Some Americans need help paying for Monjuvi. While many patients have insurance coverage or financial assistance, others have inadequate insurance coverage or no coverage at all.

To help ease the burden of rising medication costs, pharmaceutical manufacturers often launch patient assistance programs.

Qualified patients receive access to their brand-name medications at affordable rates.

However, some patients have found the application process for many patient assistance programs difficult and extensive.

Thankfully, there is a solution for patients accessing the Monjuvi patient assistance program.

How Expert Advocates Help Make Monjuvi More Affordable

Personalized Medication Assistance

Prescription Hope’s patient support services provide qualified patients with access to their medications through patient assistance programs. Our prescription assistance specialists work with you throughout the application process, handling all your forms, documents, signatures, and coordination with both healthcare providers and manufacturers.

Ongoing Patient Support

After approval, patients with Prescription Hope continue to receive long-term medication assistance services. Our team of patient advocates manages the necessary administrative tasks associated with your enrollment.

This includes form and document updates, yearly renewals, issue resolution, and even refill scheduling.

Monjuvi Price Comparison

vs

Prescription Hope logo

Estimated Retail Price*

$1,426.21

30-Day Supply

Prescription Hope Price

$70

Per Month, NO Matter The Retail Price

*Source: Drugs.com

Navigating Cancer Treatment Costs

Our biologic medication affordability access is covered under a simple $70.00 per month, per medication. That means we do not tack on added charges, hidden fees, or medication costs.

And if we can’t help you save, then you pay nothing!

Monjuvi Patient Assistance Eligibility

General Eligibility Requirements

Patients wanting to know who qualifies for prescription assistance should enroll with Prescription Hope to find out more details.

However, all programs maintain strict requirements in several general categories. Those categories include:

Income: All programs use an income threshold range to determine qualification. The range differs between programs.

Insurance: All programs use insurance coverage status as a qualification. Each program differs in level or status of coverage.

Prescription: Every program requires a valid prescription for the brand-name medication to qualify.

U.S. Residency: All patients must be legal U.S. Residents to qualify.

Simple Enrollment With Expert Support

Getting Started With Enrollment

To enroll in Monjuvi assistance through Prescription Hope services, simply follow these 6 steps in the Monjuvi application process:

  1. Submit Information: Prescription Hope’s online enrollment form only takes a few minutes to complete.
  2. Advocate Contact: Once we’ve received your completed form, a patient advocate will contact you within 1-2 business days.
  3. Document Collection: Following a quick prequalification, our team will collect all necessary documents.
  4. Provider Coordination: Our team will also coordinate with your healthcare providers to gather all needed signatures.
  5. Program Submission: After everything is in order, our team will submit your application and continue to coordinate with the manufacturer throughout the processing stage.
  6. Medication Delivery: For approved patients, medication typically ships within 2 weeks. All medications ship directly from the manufacturer to the patient’s door or doctor’s office.

Prescription Hope is not a pharmacy or manufacturer, and therefore does not ship or handle medication at any time.

Understanding Monjuvi

How Monjuvi Works

Monjuvi contains tafasitamab-cxix, a humanized Fc-modified monoclonal antibody that targets the CD19 antigen expressed on the surface of normal and malignant B lymphocytes.

Binding to CD19 mediates B-cell lysis through:

  • Antibody-dependent cellular cytotoxicity (ADCC)
  • Antibody-dependent cellular phagocytosis (ADCP)
  • Apoptosis

When used together with lenalidomide, tafasitamab enhances immune-mediated destruction of lymphoma cells, improving antitumor activity.

What Conditions Does Monjuvi Treat?

Monjuvi is indicated, in combination with lenalidomide, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from low-grade lymphoma, who are not eligible for autologous stem cell transplant (ASCT).

Monjuvi is not indicated for the treatment of patients with primary refractory DLBCL.

This indication received traditional FDA approval after conversion from its original Accelerated Approval based on confirmatory clinical trial data.

Benefits of Treatment

For appropriate adults with relapsed or refractory DLBCL who are not candidates for autologous stem cell transplant, Monjuvi may:

  • Treat relapsed or refractory diffuse large B-cell lymphoma.
  • Has demonstrated durable responses in appropriate patients during clinical studies
  • Help achieve complete or partial remission in appropriate patients.
  • Provide a targeted immunotherapy option in combination with lenalidomide.
  • Continue as monotherapy after completion of combination treatment with lenalidomide until disease progression or unacceptable toxicity.

Treatment response varies among patients and requires close monitoring by an oncology care team.

Important Safety Information and Side Effects

Monjuvi does not carry an FDA Boxed Warning.

Contraindications

The FDA Prescribing Information lists no contraindications for Monjuvi.

The most commonly reported adverse reactions include:

  • Neutropenia
  • Fatigue
  • Diarrhea
  • Cough
  • Fever (pyrexia)
  • Peripheral edema
  • Respiratory tract infection

Additional adverse reactions observed during clinical studies included:

  • Decreased appetite

Common laboratory abnormalities include:

  • Decreased neutrophil count
  • Decreased platelet count
  • Decreased hemoglobin
  • Decreased lymphocyte count

Patients should notify their healthcare provider if side effects become severe, persistent, or concerning.

Patients should discuss the following risks with their healthcare provider:

  • Serious and fatal infections
  • Myelosuppression, including neutropenia, thrombocytopenia, and anemia
  • Infusion-related reactions
  • Embryo-fetal toxicity when administered in combination with lenalidomide
  • The need to monitor for prolonged or severe neutropenia and manage treatment according to clinical guidelines, including treatment delays when appropriate

Patients require routine monitoring of complete blood counts throughout treatment. Premedication is recommended before the first infusions to reduce the risk of infusion-related reactions.

This medication is commonly administered with lenalidomide, which is contraindicated during pregnancy because it can cause severe birth defects and embryo-fetal death. Females of reproductive potential should use effective contraception during treatment and for the recommended period after the last dose. Because Monjuvi is indicated only in combination with lenalidomide, patients should comply with all pregnancy testing, contraception, and REMS requirements associated with lenalidomide.

It is not known whether tafasitamab is present in human milk. Because of the potential for serious adverse reactions in a breastfed child, breastfeeding is not recommended during treatment and for at least 3 months after the final dose.

The FDA Prescribing Information does not identify clinically significant pharmacokinetic drug interactions for tafasitamab. However, because Monjuvi is administered with lenalidomide, healthcare providers should also review the prescribing information for lenalidomide for important interaction information and required safety precautions.

Monjuvi is administered by intravenous infusion at a dosage of 12 mg/kg according to a structured treatment schedule. It is given in combination with lenalidomide for up to 12 cycles, followed by Monjuvi monotherapy until disease progression or unacceptable toxicity. Premedication is recommended before the first infusions to reduce infusion-related reactions. Patients should be monitored during and after each infusion for infusion-related reactions, and infusions should be administered according to the FDA-approved prescribing information.

Access to Multiple Medications

Support Beyond Your Medication

Sometimes, patients need access to more than one patient assistance program. When needing oncology medication assistance, some of our patients have also needed assistance with other brand-name medications.

With a list of hundreds of available medications, patients receive the same great service for every medication they qualify for.

Our service rate remains a simple $70.00 per month, per medication.

Why Choose Prescription Hope

Patient-Focused Medication Support

For 20 years, patients searching for lymphoma medication assistance, as well as other patient-centered prescription help, have trusted Prescription Hope. Our Florida-based team of patient advocates provides compassionate support and advocacy for all of our patients.

Simplified Access to Prescription Medications

From assistance program enrollment support to patient assistance services for long-term medication access, our service rate is a simple and consistent $70.00 per month, per medication.

Ongoing Prescription Assistance

Prescription Hope doesn’t just provide application assistance, but offers long-term medication support services to those looking for affordable Monjuvi access.

If you are looking to enroll in the Monjuvi patient assistance program through Prescription Hope, then be sure to complete our form today to find out how we can help you save!

Frequently Asked Questions

It's Easy!

Submit Enrollment Form

Getting started is free and easy! Simply complete the online enrollment form. 

Receive Welcome Call

An Enrollment Specialist will reach out to you for a personalized welcome call.

We Manage The Process

Your dedicated team manages your account month after month, allowing you to focus on what matters most—your health.

Helpful Articles

Latest News & Stories

Save Money On Your Prescriptions Today!